These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 31570308)

  • 21. A validation study of the 2003 American College of Cardiology/European Society of Cardiology and 2011 American College of Cardiology Foundation/American Heart Association risk stratification and treatment algorithms for sudden cardiac death in patients with hypertrophic cardiomyopathy.
    O'Mahony C; Tome-Esteban M; Lambiase PD; Pantazis A; Dickie S; McKenna WJ; Elliott PM
    Heart; 2013 Apr; 99(8):534-41. PubMed ID: 23339826
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Risk stratification of sudden cardiac death in hypertrophic cardiomyopathy.
    Miller MA; Gomes JA; Fuster V
    Nat Clin Pract Cardiovasc Med; 2007 Dec; 4(12):667-76. PubMed ID: 18033231
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Role of imaging in evaluation of sudden cardiac death risk in hypertrophic cardiomyopathy.
    Geske JB; Ommen SR
    Curr Opin Cardiol; 2015 Sep; 30(5):493-9. PubMed ID: 26154072
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Distinct ECG Phenotypes Identified in Hypertrophic Cardiomyopathy Using Machine Learning Associate With Arrhythmic Risk Markers.
    Lyon A; Ariga R; Mincholé A; Mahmod M; Ormondroyd E; Laguna P; de Freitas N; Neubauer S; Watkins H; Rodriguez B
    Front Physiol; 2018; 9():213. PubMed ID: 29593570
    [No Abstract]   [Full Text] [Related]  

  • 25. Abnormalities in sodium current and calcium homoeostasis as drivers of arrhythmogenesis in hypertrophic cardiomyopathy.
    Coppini R; Santini L; Olivotto I; Ackerman MJ; Cerbai E
    Cardiovasc Res; 2020 Jul; 116(9):1585-1599. PubMed ID: 32365196
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Hypertrophic cardiomyopathy and sudden cardiac death--ICD indications in the margin of uncertainty].
    Fauchère I; Duru F
    Praxis (Bern 1994); 2009 Aug; 98(17):941-52. PubMed ID: 19711287
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Myocardial tissue characterization by gadolinium-enhanced cardiac magnetic resonance imaging for risk stratification of adverse events in hypertrophic cardiomyopathy.
    Raiker N; Vullaganti S; Collins JD; Allen BD; Choudhury L
    Int J Cardiovasc Imaging; 2020 Jun; 36(6):1147-1156. PubMed ID: 32166506
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical meaning of isolated increase of QRS voltages in hypertrophic cardiomyopathy versus athlete's heart.
    Calore C; Zorzi A; Corrado D
    J Electrocardiol; 2015; 48(3):373-9. PubMed ID: 25595718
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Deep learning-derived 12-lead electrocardiogram-based genotype prediction for hypertrophic cardiomyopathy: a pilot study.
    Chen L; Fu G; Jiang C
    Ann Med; 2023 Dec; 55(1):2235564. PubMed ID: 37467172
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Risk stratification and role of implantable defibrillators for prevention of sudden death in patients with hypertrophic cardiomyopathy.
    Maron BJ
    Circ J; 2010 Nov; 74(11):2271-82. PubMed ID: 20962423
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hypertrophic cardiomyopathy: evaluation and treatment of patients at high risk for sudden death.
    Fananapazir L; McAreavey D
    Pacing Clin Electrophysiol; 1997 Feb; 20(2 Pt 2):478-501. PubMed ID: 9058851
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Eligibility for the Subcutaneous Implantable Cardioverter-Defibrillator in Patients With Hypertrophic Cardiomyopathy.
    Francia P; Adduci C; Palano F; Semprini L; Serdoz A; Montesanti D; Santini D; Musumeci B; Salvati A; Volpe M; Autore C
    J Cardiovasc Electrophysiol; 2015 Aug; 26(8):893-899. PubMed ID: 25996259
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Current perspectives in hypertrophic cardiomyopathy with the focus on patients in the Finnish population: a review.
    Kuusisto J; Sipola P; Jääskeläinen P; Naukkarinen A
    Ann Med; 2016 Nov; 48(7):496-508. PubMed ID: 27460395
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Assessment of the relationship between the ambulatory electrocardiography-based micro T-wave alternans and the predicted risk score of sudden cardiac death at 5 years in patients with hypertrophic cardiomyopathy.
    Özyılmaz S; Püşüroğlu H
    Anatol J Cardiol; 2018 Sep; 20(3):165-173. PubMed ID: 30152798
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Contemporary strategies for risk stratification and prevention of sudden death with the implantable defibrillator in hypertrophic cardiomyopathy.
    Maron BJ; Maron MS
    Heart Rhythm; 2016 May; 13(5):1155-1165. PubMed ID: 26749314
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Left ventricular mechanical dispersion is associated with nonsustained ventricular tachycardia in hypertrophic cardiomyopathy.
    Jalanko M; Tarkiainen M; Sipola P; Jääskeläinen P; Lauerma K; Laine M; Nieminen MS; Laakso M; Heliö T; Kuusisto J
    Ann Med; 2016 Sep; 48(6):417-427. PubMed ID: 27249556
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Subcutaneous Implantable Cardioverter Defibrillator in Patients With Hypertrophic Cardiomyopathy: An Initial Experience.
    Weinstock J; Bader YH; Maron MS; Rowin EJ; Link MS
    J Am Heart Assoc; 2016 Feb; 5(2):. PubMed ID: 26873684
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prognostic Role of Late Gadolinium Enhancement in Patients With Hypertrophic Cardiomyopathy and Low-to-Intermediate Sudden Cardiac Death Risk Score.
    Todiere G; Nugara C; Gentile G; Negri F; Bianco F; Falletta C; Novo G; Di Bella G; De Caterina R; Zachara E; Re F; Clemenza F; Sinagra G; Emdin M; Aquaro GD
    Am J Cardiol; 2019 Oct; 124(8):1286-1292. PubMed ID: 31447011
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical outcomes associated with sarcomere mutations in hypertrophic cardiomyopathy: a meta-analysis on 7675 individuals.
    Sedaghat-Hamedani F; Kayvanpour E; Tugrul OF; Lai A; Amr A; Haas J; Proctor T; Ehlermann P; Jensen K; Katus HA; Meder B
    Clin Res Cardiol; 2018 Jan; 107(1):30-41. PubMed ID: 28840316
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical Outcomes in Patients With Nonobstructive, Labile, and Obstructive Hypertrophic Cardiomyopathy.
    Lu DY; Pozios I; Haileselassie B; Ventoulis I; Liu H; Sorensen LL; Canepa M; Phillip S; Abraham MR; Abraham TP
    J Am Heart Assoc; 2018 Feb; 7(5):. PubMed ID: 29478967
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.